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Diabetic nephropathy is one of the most signiﬁcant microvascular complications in patients with type 2 diabetics. The concise
mechanism of diabetic nephropathy is unknown and there is no successful treatment. The objective of study was to investigate
eﬀects of Chinese herbs (Tangshen Formula) on diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
OLETFratsandLETOratsweredividedintofourgroups:LETOcontrol,OLETFdiabetics,OLETFdiabeticstreatedwithTangshen
Formula, and OLETF diabetics treated with Monopril. Body weight, blood glucose, and 24h urinary proteins were measured once
every four weeks. Blood samples and kidney tissues were obtained for analyses of total cholesterol, triglyceride, whole blood
viscosity, plasma viscosity, and pathohistological examination at 36 and 56 weeksrespectively. Untreated OLETF rats displayed
diabetic nephropathy over the study period. Treatment of OLETF rats with Tangshen Formula attenuated the increases in blood
glucose, body weight, 24h urinary protein content, serum total cholesterol, whole blood viscosity and plasma viscosity at certain
time. Treatment with Tangshen Formula also reduced glomerulosclerotic index and interstitial ﬁbrotic index seen in OLETF rats.
In conclusion, Tangshen Formula could attenuate the development of diabetic nephropathy in OLETF rat diabetic model.
1.Introduction
Diabetic nephropathy (DN) is one of the most important
microvascular complications associated with type 2 diabetic
patients and has emerged as a leading cause of the end-
stage renal disease in developed countries [1, 2]. DN is
characterizedbystructuralabnormalitiesofkidneyincluding
hypertrophy of both glomerular and tubular elements,
increase in the thickness of glomerular basement mem-
branes, and progressive accumulation of extracellular matrix
components, eventually leading to proteinuria and renal
failure[3].Despiteimplementationofintensiveglycemicand
antihypertensive control, DN remains an important clinical
problem [2] and new therapeutic agents are needed for the
treatment of this condition.
A useful model of the human type II diabetes mellitus
is the Otsuka Long-Evans Tokushima Fatty (OLETF) rat.
This model is characterized by the development of late-
onset hyperglycemia, mild obesity, and the associated
diabetic complications. At 22 weeks of age the OLETF rats
develop overt albuminuria and at 30 weeks, OLETF showed
signiﬁcant proteinuria and morphological changes in the
kidney such as glomerular hypertrophy and extracellular
matrix expansion. At 54 weeks, OLETF rats developed
advanced kidney injuries such as heavy proteinuria,
diﬀuse glomerulosclerosis, nodular lesions and severe
tubulointerstitial ﬁbrosis, which are resemble to late stage of
human DN. Thus, the OLETF rat is considered to be a useful
animal model to study type 2 diabetic nephropathy [4–6].
In China, traditional herbal medicines have been widely
used for the treatment of diabetes and its complications for
thousands of years. Recently they have received worldwide
attention and are becoming promising sources of new2 Evidence-Based Complementary and Alternative Medicine
therapeutic agents for diabetic nephropathy [7]. One such
medicine is the Tangshen Formula. It is composed of several
herbs and formulated according to Traditional Chinese
Medicine teachings. In our clinical study, we found that
Tangshen Formula had improvement eﬀects on proteinuria
and hyperlipidemia in DN patients [8]. However, to date,
there is little experimental evidence to explain these eﬀects.
To this end, we investigated the eﬀect of the Tangshen For-
mula treatment on renal function, morphological changes,
serum lipid, and hemorheology in the OLETF rat.
2.MaterialsandMethods
2.1. Animals and Experimental Design. Four-week-old male
OLETF rats and age-matched Long-Evans Tokushima
Otsuka (LETO) rats were kindly provided by Tokushima
Research Institute (Otsuka Pharmaceutical, Tokushima,
Japan). All rats were housed at 22 ± 3◦Ca n d5 0± 10%
humidityusinga12hlight/darkcycle.Allanimalsweregiven
free access to standard rat chow and water. Four groups of
rats were prepared at 12 weeks of age:
(1) non-diabetic LETO rats given distilled water (no
treatment, n = 20, LETO control),
(2) diabetic OLETF rats given water (no treatment,
n = 15, OLETF control),
(3) diabetic OLETF rats administered Tangshen Formula
(1.60g/kg body weight/day, n = 15, OLETF + TSF),
(4) OLETF rats administered Monopril (Bristol-Myers
Squibb, USA, 0.833mg/kg body weight/day, n = 15,
OLETF + monopril).
All drugs were dissolved in distilled water and administered
once daily by gastric gavage. The powdered formulation of
Tangshen Formula was composed of radix astragali (24g),
radix rehmanniae (15g), radix notoginseng (2g), prepared
radix et rhizome rhei with wine (8g), fructus aurantii
(6g), fructus corni (11g) and ramulus euonymi (12g)
(Tianjiang Pharmacology Co. Ltd, China). The experimental
extraction procedure was identical to that used for the
clinical preparation of the formula. Brieﬂy, herbs were well
mixed and soaked in distilled water for 30min, boiled in
1 0v o l u m e so fw a t e r( v / w )f o r1h ,a n de x t r a c t e dt w i c e .T h e
extract was ﬁltrated and condensed to the concentration of
1g/ml and processed to powder by spray drying. The volume
administered to the animals was calculated to be 1ml/100g
body weight [9].
Ten rats from the LETO control group and seven rats
from the other three groups were sacriﬁced at 36 weeks of
age. The remaining rats in each group were sacriﬁced at 56
weeks of age. The endpoints of experiment were determined
according to pathological changes during life span of OLETF
rats. Rats were sacriﬁced by intraperitoneal injection of
chloral hydrate. Blood samples were then collected from the
abdominal aorta, and kidneys were removed and separated
intotwopiecesforhistopathologicalexamination.Thisstudy
was approved by the Ethics Committee of China-Japan
Friendship Institute of Clinical Medicine and performed in
accordance with Guiding Principles for the Care and Use of
Laboratory Animals.
2.2.DeterminationofBody Weight,Blood SampleandUrinary
Protein. Body weight of rats was measured at 4-week
intervals. Blood was sampled from the tail vein at 4-week
intervals, and blood glucose levels measured by One Touch
Ultrablood glucose monitoring system (LifeScan, USA).
Rats were housed individually in metabolic cages (Fengshi,
China) for 24-h urinary collection at 4-week intervals.
Rats were sacriﬁced and aortic blood was collected
and divided into 2 parts. One part of blood samples was
collected into tubes without anticoagulant and centrifuged
at 3000g/min and 4◦C for 15min. Serum was separated and
totalcholesterol,triglycerides,ureanitrogen,creatinine,total
protein, and albumin were measured using a CD-1600CS
hematology analyzer (Abbott Labs, USA).
2.3. Measurement of Blood Viscosity. The other part of
blood was collected into tubes containing Na2EDTA. Blood
viscosity was measured at 37◦C with a coaxial cylinder
microviscometer (BV-100, China) at a shear rate of 0.945s
and 94.5s followed by plasma viscosity determination after
centrifugation.
2.4. Histological Examination of the Kidney. Sections of
kidney tissue were removed and immediately ﬁxed in 10%
phosphate buﬀered formalin solution and embedded in
paraﬃn. Sections (3-μm) from each sample were cut and
stained with periodic acid Schiﬀ’s stain for determination
of glomerulosclerosis. The degree of glomerulosclerosis,
deﬁned as a thickening of the basement membrane and
mesangial expansion, was evaluated as described previously
[10]. In brief, the prepared kidney sections were observed
under an Olympus BX51 light microscope (Olympus, Japan)
at a magniﬁcation of ×400 with an Olympus DP70 digital
imaging system (Olympus, Japan). Forty glomeruli in each
kidney were graded in accordance with their severity of
glomerular damage (0, normal; 1, slight glomerular damage,
the mesangial matrix and/or hyalinosis with focal adhesion
involving <25% of the glomerulus; 2, sclerosis of 26–50%;
3, sclerosis of 51–75%; and 4, sclerosis of >75% of the
glomerulus). The glomerulosclerotic indices were calculated
using the formula: glomerulosclerotic index=(1 ×n1)+(2 ×
n2) + (3 × n3) + (4 × n4)/n0+n1+n2+n3+n4, where nx
is number of glomeruli in each grade of glomerulosclerosis.
The observer was blinded to all tissue samples.
Tubulointerstitial and vascular damage was assessed on
periodic acid Schiﬀ’s-stained paraﬃn sections at a magni-
ﬁcation of ×100 using a similar scoring system (0–4) as
described previously in detail [11].
2.5. Statistics. Data are presented as mean ± SEM unless
statedotherwise.Signiﬁcantdiﬀerencesbetweengroupswere
compared using ANOVA with P<. 05 being considered
statistically signiﬁcant.Evidence-Based Complementary and Alternative Medicine 3
Table 1: Rheological parameters in control and Tangshen Formula treated rats.
36 weeks of age 56 weeks of age
Groups
Whole blood Whole blood Plasma Whole blood Whole blood Plasma
viscosity viscosity viscosity viscosity viscosity viscosity
(0.945s) (mPa·S) (94.5s) (mPa·S) (mPa· S) (0.945s) (mPa·S) (94.5s) (mPa·S) (mPa·S)
LETO 4.45 ±0.14 17.90 ±1.18 1.29 ±0.03∗∗ 4.37 ±0.14∗∗ 18.42 ±1.04∗∗ 1.31 ±0.03∗∗
OLETF 4.67 ±0.12 16.78 ±0.87 1.42 ±0.03 5.56 ±0.15## 26.97 ±1.38## 1.51 ±0.06
OLETF + TSF 4.74 ±0.28 14.05 ±0.74 1.33 ±0.02∗∗ 4.85 ±0.06∗ 20.96 ±2.22∗## 1.35 ±0.05∗
OLETF + Monopril 4.67 ±0.14 14.58 ±1.00 1.37 ±0.02 5.64 ±0.38# 26.61 ±1.10## 1.40 ±0.05
Data represent mean ± SEM; ∗P<. 05, ∗∗P<. 01 versus control OLETF rats; #P<. 05, ##P<. 01 compares the 36 and 56 weeks of age data groups.
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Figure 1: Eﬀects of Tangshen Formula and Monopril on body
weight in the rats during the 56 week treatment period. Data
represent mean ± SEM; ∗P<. 05 and ∗∗P<. 01 compared to
control OLETF rats.
3. Results
Body weight of OLETF rats was heavier than that of LETO
rats from 12 to 36 weeks (Figure 1). However from weeks
40 to 48, body weight of OLETF rats treated with Tangshen
Formula was not signiﬁcantly diﬀerent as compared with
that of LETO rats, but it was signiﬁcantly diﬀerent than that
of OLETF rats treated with water and Monopril. Moreover,
at weeks 52 and 56, no signiﬁcant diﬀerence of body weight
wad observed among all these groups.
B l o o dg l u c o s el e v e l sf o rt h eL E T Oc o n t r o lr a t sd i d
not change throughout the study period (Figure 2). Blood
glucose of the age-matched OLETF rats was statistically
higher than those of LETO rats throughout the study period
(Figure 2). Compared to control OLETF rats, blood glucose
of OLETF rats treated with Tangshen Formula exhibited
statistically lower blood glucose at 52 and 56 weeks of age.
Blood glucose of OLETF rats treated with Monopril also
became elevated during the study period. Except at weeks
40 and 52, blood glucose in this group was not signiﬁcantly
diﬀerent from the OLETF control group (Figure 2).
Urinary protein in all OLETF rats gradually and continu-
ally increased during the entire study period compared with
levels in the LETO rats that remained unchanged (Figure 3).
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Figure 2: Eﬀect of Tangshen Formula and Monopril on blood
glucose in the rats during the 56 week treatment period. Data
represent mean ± SEM; ∗P<. 05 and ∗∗P<. 01 compared to
control OLETF rats.
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Figure 3: Eﬀects of Tangshen Formula and Monopril on 24-h
urinary protein in the rats during the 56 week treatment period.
Data represent mean ± SEM; ∗P<. 05 and ∗∗P<. 01 compared to
control OLETF rats.
Rats treated with Tangshen Formula had signiﬁcantly lower
levelsof24hurinaryproteincomparedtothecontrolOLETF
ratsstartingat36weeksofage.Urinaryproteininratstreated
with Monopril was only signiﬁcantly lower than that the
OLETF control group at weeks 24, 36 and 44 (Figure 3).4 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Periodic acid-Schiﬀ staining of glomeruli of the rats at 36 weeks of age: (a) control LETO group; (b) control OLETF group, (c)
OLETF + TSF group, (d) OLETF+Monopril group; and at 56 weeks of age: (e) control LETO group; (f) control OLETF group, (g) OLETF
+ TSF group, (h) OLETF + Monopril group, In diabetic OLETF rats, mesangial expansion accompanied by an accumulation of extracellular
matrix and glomerular capillary wall thickening occurs at 36 weeks of age. Diﬀuse glomerularsclerosis and mesangial matrix expansion
happened at 56 weeks of age. These glomerular changes are ameliorated by TSF and monopril treatment. Pictures is at the magniﬁcation of
×400.
Table 2: Biochemical indices of control and Tangshen Formula treated rats at 36 and 56 weeks of age.
weeks LETO OLETF OLETF + TSF OLETF + Monopril
Total cholesterol (mmol/L) 36 2.71 ±0.07 2.51 ±0.15 2.59 ±0.08 2.77 ±0.30
56 2.00 ±0.06∗∗## 4.27 ±0.36## 2.21 ± 0.21∗∗ 3.94 ±0.47
Triglyceride (mmol/L) 36 0.26 ±0.04∗∗ 1.15 ±0.12 1.01 ±0.13 0.71 ±0.05∗
56 0.21 ±0.01∗∗ 1.30 ±0.26 0.96 ±0.07 1.07 ±0.17#
Total protein (mmol/L) 36 60.30 ±0.76 58.86 ±1.08 59.29 ±1.02 58.14 ±1.06
56 70.25 ±0.99∗∗## 67.17 ±1.39## 73.17 ±2.04∗∗## 69.20 ± 1.39##
Albumin (mmol/L) 36 32.00 ±0.42 30.86 ±0.34 30.71 ±0.52 30.57 ±0.90
56 32.06 ±0.39∗ 28.62 ±0.78## 31.83 ±1.25∗∗ 29.26 ±0.67
Urea nitrogen (mmol/L) 36 8.22 ±0.26 7.53 ±0.87 6.97 ±0.50 8.52 ±0.50
56 5.28 ±0.17∗∗## 7.86 ±1.02 6.60 ±0.58 8.07 ±1.12
Creatinine (μmol/L) 36 89.22 ± 3.29∗∗ 68.00 ±1.89 68.57 ±1.19 70.86 ±1.47
56 69.75 ±0.44∗∗## 58.73 ±3.01## 53.18 ±1.69## 55.04 ± 2.60##
Data represent mean ± SEM, ∗P<. 05, ∗∗P<. 01 versus control OLETF rats; #P<. 05, #P<. 01 compares the 36 and 56 weeks of age data groups.
There was no statistical diﬀerence in whole blood viscos-
ity at 0.945s and 94.5s among the four groups at 36 weeks of
age. However, whole blood viscosity for control OLETF rats
was markedly higher than those of LETO rats at 56 weeks of
age (Table 1). These two indices were signiﬁcantly lower in
OLETF rats treated with Tangshen Formula compared with
those of the control (untreated) OLETF rats. Monopril had
no eﬀect on whole blood viscosity (Table 1).
Plasma viscosity of control OLETF rats was markedly
increased compared with the LETO rats at 36 and 56
weeks of age. Plasma viscosity of the Tangshen Formula
treated OLETF rats were signiﬁcantly lower than that of the
untreated rats at weeks 36 and 56 (Table 1).
There was no statistical diﬀerence in total cholesterol
between control OLETF rats and LETO rats at 36 weeks
of age (Table 2). Compared with the LETO rats, however,
total cholesterol was signiﬁcantly increased (P<. 01) in
untreated OLETF rats at 56 weeks of age. Triglyceride levels
in untreated OLETF rats were markedly increased compared
to the LETO rats at 36 and 56 weeks of age (P<. 01).
Serum total protein and albumin of control OLETF rats
were similar to LETO rats at 36 weeks of age; however,Evidence-Based Complementary and Alternative Medicine 5
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Figure 5: Eﬀect of Tangshen Formula and Monopril on glomeru-
losclerotic index and interstitial ﬁbrotic index in the rats at 36 and
56 weeks of age. Data represent as mean ± SEM; ∗P<. 05, ∗P<. 01
versus control OLETF rats.
they were statistically lower at 56 weeks of age. There was no
diﬀerence in urea nitrogen levels between LETO and control
OLETF rats at 36 weeks of age but urea nitrogen levels of
control OLETF rats were higher than those of LETO rats at
56 weeks of age. Serum creatinine levels in untreated OLETF
rats were signiﬁcantly lower than in LETO rats at both 36
and 56 weeks of age (Table 2). This ﬁnding suggests that
glomerular perﬁltration in diabetic kidneys may be taking
place. Tangshen Formula improved cholesterol, total protein
andalbuminofOLETFratsat56weeksofage(P<. 01)while
triglyceride levels of OLETF rats were signiﬁcantly decreased
by Monopril at 36 weeks of age (P<. 05).
Glomerular lesions in OLETF rats were characterized by
hyalinosis, thickening of the basement membrane, mesangial
expansion and sclerotic lesions. These pathological changes
at 56 weeks of age were more severe than those at 36 weeks
of age. Interstitial ﬁbrosis in OLETF rats was focal and mild
at 36 weeks of age while at 56 weeks of age severe changes
occurred that included protein cast, tubular dilation or atro-
phy, and inﬁltration of inﬂammatory cells. Treatment with
Tangshen Formula and Monopril signiﬁcantly suppressed
glomerulosclerosis in OLETF rats. Interstitial ﬁbrotic lesions
in OLETF rats were signiﬁcantly improved by treatment with
Tangshen Formula at both 36 and 56 weeks of age (Figure 4).
Glomerulosclerosis index and interstitial ﬁbrosis index in
untreated OLETF rats increased signiﬁcantly compared with
those in LETO rats at 36 and 56 weeks of age. Figure 5 shows
that the Tangshen Formula and Monopril treatment both
attenuated the increase in glomerulosclerosis index at 36 and
56 weeks while only Tangshen Formula was able to attenuate
the increase in the interstitial ﬁbrosis.
4. Discussion
In recent years the number of people suﬀering from the end-
stage renal disease has increased worldwide. Approximately
one third of ESRD results from diabetic nephropathy (DN).
Eﬀective treatment of DN is an important challenge to
nephrologists today [12]. Animal studies show that the
renin-angiotensin system (RAS) plays an important role in
the pathogenesis of DN. Clinically, inhibition of the RAS by
angiotensin converting enzyme inhibition and angiotensin
receptor blockade (ARB) provide renoprotective beneﬁts.
Use of these drugs has been substantiated by both clinical
trials and animal studies [13]. As a consequence, use of
RAS antagonists has become the standard of care in diabetic
patients with kidney disease and the utility of these agents
continues to increase [14]. However, although it appears that
such treatment slows the progression of DN development to
ESRD, it does not stop or reverse the pathology.
Traditional Chinese Medicine also exhibits beneﬁcial
eﬀects on DN and is becoming a promising therapy [15, 16].
However,atthistime,littleexperimentalevidenceisavailable
to explain these eﬀects. It is important, therefore, to further
investigate the eﬀects of Traditional Chinese Medicine and
angiotensin converting enzyme inhibition on DN in experi-
mental models of diabetes.
OLETF rats are widely used in many laboratories as a
model of type 2 diabetes in humans. OLETF rats are char-
acterized by late-onset hyperglycemia, a mild and chronic
course of diabetes mellitus, and the associated complications
of diabetes. Diabetes develops in almost all male OLETF
rats by 25 weeks of age. As the disease progresses, renal
complication becomes inevitable in this animal [4, 17].
Hyperglycemia is a critical factor in the development
of diabetic nephropathy. It is associated with an increase
in mesangial cell proliferation and hypertrophy, as well
as increased matrix production and basement membrane
thickening [18,19].Theassociatedhyperglycemiamightalso
upregulate VEGF expression in podocytes [20] which could
markedly increase vascular permeability [21, 22]. Intensive
glycemic control could, therefore, slow the development of
diabetic nephropathy [23, 24]. In this investigation, Tang-
shen Formula had a signiﬁcant eﬀect on limiting the increase
in blood glucose levels in OLETF rats at 52 weeks of age. In
addition to its eﬀects on blood glucose, Tangshen Formula
also had a positive renoprotective eﬀect. Improvement of
the nephropathy observed in the Tangshen Formula treated
group may be partially dependent on the eﬀects Tangshen
Formula has on glucose metabolism.6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: A diagram demonstrates the possible eﬀect of Tangshen Formula in ameliorating diabetic nephropathy. At the early or middle
state of DN, TSF improve proteinuria and mild renal pathological changes by decreasing plasma viscosity and at the late stage of DN, TSF
alleviated massive proteinuria and severe glomerulosclerosis by regulating the levels of cholesterol, glucose and rheological changes. The
deﬁnitions of abbreviations and symbols in the diagram are DN: diabetic nephropathy; TSF: Tangshen Formula.
We observed an increase in total serum cholesterol in
OLETF rats over the study period (approximately 70%,
P<. 01), while triglyceride levels increased by 13%. The
increase in cholesterol is believed to be a compensatory
production of lipids in the liver stimulated by hypoal-
buminemia [25]. Circulating lipids are known to bind
to extracellular matrix molecules where they undergo
oxidation and increase the formation of reactive oxygen
species (ROS) [26]. ROS reduce endothelium-derived
vasodilators/growth inhibitors (such as prostacyclin and
nitric oxide) and increase the formation of endothelium-
derived vasoconstrictors/growth promoters (such as angi-
otensin II and endothelin-1) which are known to have
signiﬁcant renal pathophysiological eﬀects [27, 28]. It is
possible, therefore, that the associated hyperlipidemia could
cause or contribute to renal injury [26, 29, 30].
We showed that Tangshen Formula and Monopril had
beneﬁcial eﬀects on serum lipids. Total cholesterol was sta-
tisticallylowerinOLETFratstreatedwithTangshenFormula
at 56 weeks of age than control OLETF rats, while Monopril
lowered triglyceride levels of OLETF rats at 36 weeks of age.
It is not surprising that Monopril had a lipid-lowering eﬀect
since angiotensin converting enzyme inhibitors are known
to lower serum total cholesterol and triglycerides in DN
patients [31]. This reduction in triglycerides, however, was
not sustained over the treatment period. The Chinese herbs,
radix notoginseng, radix astragali and radix et rhizome rhei,
all of which are present in the Tangshen Formula, have been
reported to lower total serum cholesterol and triglyceride
levels [32–34]. The present study showed that Tangshen
Formula reduced only total cholesterol in OLETF rats.
These diﬀerences may be due to dosage or drug administra-
tion since only one dose of the Tangshen Formula was used
in this study. It is possible that the lipid-lowering eﬀect of the
Tangshen Formula may be associated with its renoprotective
action.
Changes in blood rheology are an important factor
that can lead to microvascular complications in diabetes.Evidence-Based Complementary and Alternative Medicine 7
Hyperviscosity-related resistance to glomerular blood ﬂow
causes a compensatory elevation in glomerular hydrostatic
pressure, which leads to an increase in protein permeability
across the glomerular basement membrane. The increased
viscosity may also lead to a cessation of glomerular blood
ﬂow and subsequent capillary thrombosis and glomeru-
losclerosis [35–38]. Our study showed that Tangshen For-
mula can reduce whole blood viscosity and plasma viscosity
in OLETF rats, thereby potentially minimizing or preventing
the pathological changes in the kidneys of OLETF rats.
The results from this study suggest that the beneﬁcial
eﬀect of Tangshen Formula may be due to its ability to
limit the development of hyperlipidemia as well as its
beneﬁcial eﬀects on renal hemorheology in the OLETF rats.
Tangshen Formula could reduce plasma viscosity at 36 weeks
age, and at 56 weeks of age, Tangshen formula exhibits
renoprotective eﬀects by reduce the protein excretion and
alleviated histological changes, the eﬀects may be related to
rectify the abnormality lipid metabolism, hyperglycemia and
hemorheology disorder. This theory is illustrated inFigure 6.
In conclusion, we found that Tangshen Formula atten-
uates the development of diabetic nephropathy in type 2
diabetic OLETF rats. Tangshen Formula may, therefore,
represent a potentially new therapeutic strategy in the
treatment of diabetic nephropathy in type 2 diabetes.
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